Intravenous Misuse of Methadone, Buprenorphine and Buprenorphine-Naloxone in Patients Under Opioid Maintenance Treatment: A Cross-Sectional Multicentre Study. Lugoboni F, Zamboni L, Cibin M, Tamburin S; Gruppo InterSERT di Collaboraz…

Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Haight, Barbara RAndersen, James L. et al. Lancet. 2019 Feb 18. pii: S0140-6736(18)3…

Monthly buprenorphine injections effective for opioid use disorders Study results on long-acting injection formulation now published. (NIH – National Institutes of Health, USA, 19.02.2019) https://www.nih.gov/news-events/news-releases/monthly-bupr…

Lund/Mannheim, 12. Februar 2019 – Wie Camurus (NASDAQ STO: CAMX) heute bekannt gab, ist das wöchentlich oder monatlich anzuwendende Buvidal® (Buprenorphin-Depotlösung zur subkutanen Injektion) ab sofort in Deutschland verfügbar. Buvidal® ist das ers…

No increased pain among opioid-dependent individuals treated with extended-release naltrexone or buprenorphine-naloxone: A 3-month randomized study and 9-month open-treatment follow-up study. Latif ZE, Solli KK, Opheim A, Kunoe N, Benth JŠ, Krajci…

Buprenorphine for the treatment of posttraumatic stress disorder. Lake EP, Mitchell BG, Shorter DI, Kosten T, Domingo CB, Walder AM. Am J Addict. 2019 Jan 21. doi: 10.1111/ajad.12860.  Abstract https://www.ncbi.nlm.nih.gov/pubmed/30664299…